Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
"This book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer…
Table of contents:; History of Cancer Immunotherapy -- Section I: Basic Principles of Tumor Immunology -- Section II: Cancer Immunotherapy Targets and Classes -- Section III: Immune Function in Cancer Patients -- Section IV: Disease-Specific Treatments and Outcomes -- Section V: Regulatory Aspects …
c.1 BC Cancer Agency VAN Library | Available |
Contents:; Introduction -- When to refer a patient for CAR-T cell therapy -- Optimizing the apheresis product -- CAR T cells: cell processing laboratory considerations -- Peri-CAR-T cell management -- Management of cytokine release syndrome -- Special considerations for ICU management of patients r…
c.1 BC Cancer Agency VAN Library | On Loan, due Monday, May 13, 2024 | ||
c.1 BC Cancer Agency ARHCC Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency ARHCC Library | Available | ||
c.1 BC Cancer Agency KEL Library | Available |
"Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia…
Table of Contents:; 1. HISTORY OF IMMUNOTHERAPY -- 2. PRINCIPLES OF IMMUNOLOGY AND IMMUNOTHERAPY -- 3. CYTOKINES IN IMMUNOTHERAPY -- 4. IMMUNE CHECKPOINT INHIBITORS -- 5. BACILLUS CALMETTE-GUÉRIN - 6. ORAL IMMUNOMODULATORY AGENTS --7. ACTIVE IMMUNITY: VACCINE THERAPY -- 8. PASSIVE/ADOPTIVE IMMUNOTH…
c.1 BC Cancer Agency VIC Library | Available |
Table of Contents:; 1. Immunotherapy administration; 2. Immunotherapy; 3. Cancer immunotherapy; 4. CAR T-cell therapy; 5. Cytokine release syndrome; 6. Developming infrastructure; 7. Immunotherapy toxicities; 8. Checkpoint inhibitors; 9. Toxicity managment; 10.Oncolytic viruses
c.1 BC Cancer Agency VAN Library | On Loan, due Tuesday, January 9, 2024 | ||
c.2 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency KEL Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |